摘要：Objective: To investigate the effects of Shenqi Fuzheng Injection Combined with chemotherapy on peripheral blood, immune function and tumor markers in patients with breast cancer. Methods: A total of 92 cases of breast cancer treated by modified radical mastectomy in our hospital from January 2017 to December 2017 were selected as the research subjects and were randomly divided into 46 cases in the observation group and 46 cases in the control group. The patients in the control group began chemotherapy after 2 weeks of surgery, and the observation group was given Shenqi Fuzheng Injection on the basis of the control group. The levels of leukocyte, platelet, hemoglobin, T cell subgroup, carcinoembryonic antigen (CEA), cancer antigen 153 (CA153) and carbohydrate antigen 125 (CA125) were measured and compared of patients in two groups. Results: Before treatment, there was no significant difference in white blood cell, platelet and hemoglobin between the two groups. After treatment, the white blood cells, platelets and hemoglobin in the observation group were (3.56±0.10)×109/L, (137.47±23.58)×109/L, (116.72±15.75) g/L, and the white cells, platelets and hemoglobin in the control group were (2.85±0.18)×109/L, (126.76±21.34)×109/L, (103.36±20.51) g/L, respectively, all the indexes decreased than before treatment, moreover the decrease of control group is more obvious than observation group, and the difference was statistically significant. Before treatment, there was no significant difference in CD3+, CD4+, CD8+and CD4+/CD8+between the two groups. After treatment, the CD3+, CD4+and CD4+/CD8+in the observation group were (58.02±12.77)%, (50.79±7.45)% and (2.13±0.69), which were significantly higher than those before the treatment, and increased compared with the control group in the corresponding period, the difference was statistically significant. Before treatment, there was no significant difference in CEA, CA153 and CA125 between the two groups. After treatment, the CEA, CA153 and CA125 of the observation group were (16.70±3.71) μg/L, (13.11±3.70) U/mL and (11.25±1.73) U/mL, and in the control group they were (21.71±4.24) μg/L, (20.31±4.21) U/mL and (17.78±2.36) U/mL, respectively, the CEA, CA153 and CA125 in two groups were all lower than those before treatment, and the indexes of the observation group were decreased more significantly than those of the control group, the differences were statistically significant. Conclusion: Shenqi Fuzheng Injection Combined with chemotherapy in peripheral blood and immune function significantly improved in patients with breast cancer, and a significant decrease in the level of tumor markers.
